12
Clinical Trials associated with Insulin human biosimilar(Wockhardt Ltd.) / Not yet recruitingNot Applicable A RANDOMIZED, SINGLE CENTER, DOUBLE BLIND, TWO TREATMENT, TWO-PERIOD, CROSSOVER GLUCOSE CLAMP STUDY TO TEST FOR BIOEQUIVALENCE BETWEEN WOCKHARDTâ??S WOSULIN® 30/70 (100 IU/mL) {BIPHASIC ISOPHANE INSULIN INJECTION/ 70% HUMAN INSULIN ISOPHANE SUSPENSION AND 30% HUMAN INSULIN INJECTION (r-DNA ORIGIN)} AND HUMULIN® 70/30 (100 U/mL) {70% HUMAN INSULIN ISOPHANE SUSPENSION AND 30% HUMAN INSULIN INJECTION (rDNA origin)} IN HEALTHY SUBJECTS. - Clamp Study
/ RecruitingNot Applicable A RANDOMIZED, SINGLE CENTER, DOUBLE BLIND, TWO TREATMENT, TWO-SEQUENCE, TWO PERIOD, CROSSOVER GLUCOSE CLAMP STUDY TO TEST FOR BIOEQUIVALENCE BETWEEN WOCKHARDTâ??S WOSULIN® N (100 IU/mL) {ISOPHANE INSULIN HUMAN, SUSPENSION, r-DNA ORIGIN} AND HUMULIN® N (100 U/mL) {HUMAN INSULIN (r-DNA ORIGIN) ISOPHANE SUSPENSION}, IN HEALTHY SUBJECTS. - Clamp Study
/ Active, not recruitingPhase 1 A RANDOMIZED, SINGLE CENTER, DOUBLE BLIND, TWO-PERIOD, CROSSOVER GLUCOSE CLAMP STUDY TO TEST BIOEQUIVALENCE BETWEEN TWO FORMULATIONS OF RECOMBINANT HUMAN INSULINS; WOSULIN R (200 IU) WITH WOSULIN R (100 IU) IN HEALTHY SUBJECTS. - W-WOS(R)-103
100 Clinical Results associated with Insulin human biosimilar(Wockhardt Ltd.)
100 Translational Medicine associated with Insulin human biosimilar(Wockhardt Ltd.)
100 Patents (Medical) associated with Insulin human biosimilar(Wockhardt Ltd.)
100 Deals associated with Insulin human biosimilar(Wockhardt Ltd.)